Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

Eli Lilly and Company530 enrolled

Overview

The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

530

Conditions

Schizophrenia

Interventions

OlanzapineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion: 1. You must be between the ages of 18 and 75. If you have reached your 76th birthday, you will not be able to participate 2. You must have been diagnosed with schizophrenia 3. You must be able to visit the doctor's office as scheduled for the next 7 months Exclusion: 1. You have a serious medical illness, such as heart, liver, or kidney disease (Note: If you are uncertain about a particular condition, discuss it with your doctor.) 2. You are either pregnant or breastfeeding

Locations (60)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

El Centro, California, United States

Unnamed facility

Glendale, California, United States

Unnamed facility

Sherman Oaks, California, United States

Unnamed facility

Middleton, Connecticut, United States

Unnamed facility

Norwich, Connecticut, United States

Unnamed facility

Melbourne, Florida, United States

Unnamed facility

Miami, Florida, United States

Unnamed facility

Atlanta, Georgia, United States

Unnamed facility

Chicago, Illinois, United States

Unnamed facility

Hoffman Estates, Illinois, United States

...and 50 more locations